Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03922659
Other study ID # 2019-12-TMSCBT-H
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 30, 2019
Est. completion date December 2021

Study information

Verified date March 2021
Source Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Ying Peng, MD, PhD
Phone +86-13380051581
Email pengy2@mail.sysu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Heroin dependence is one of most common substance dependence, which brings great burden on health worldwide. Heroin dependence may lead to immunosuppression and cognitive impairments. Once heroin dependence is developed, it will be difficult to recover and easy to relapse. Although many efforts had been made in the treatment of heroin dependence, the annual recurrence of heroin dependence with traditional therapies would be up to 90%. Repetitive transcranial magnetic stimulation (rTMS) on the dorsolateral prefrontal cortex (DLPFC) or cognitive behavioral therapy (CBT) each alone was reported to have some effect on preventing from relapse of substance dependence. In order to test whether combined therapy of high frequency rTMS (hf-rTMS) with CBT is better for preventing from relapse of heroin dependence, we recruit patients with heroin dependence to participate this study. The study is a factorial designed and the patients will be assigned into one of the following six groups randomly: (1) regular treatment (symptomatic treatment) with blank TMS; (2) regular treatment (RT) with blank TMS and CBT; (3) RT with right DLPFC hf-rTMS; (4) RT with right DLPFC hf-rTMS and CBT; (5) RT with left DLPFC hf-rTMS; (6) RT with left DLPFC hf-rTMS and CBT. TMS was given 5 days per week for total 2 weeks using uniform scheme (5 seconds of 10Hz stimulation per train, 30 trains per day with inter-train interval of 20 seconds). CBT will be given once per week for total 8 weeks. The patients will be followed up for 6 months. Recurrence of heroin dependence, duration of abstention, heroin/drug intake, craving for heroin and other cognitive psychological assessments will be recorded and compared among the 6 treatment groups and the efficacy of combined therapy of rTMS with CBT will be evaluated in our study.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 2021
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Diagnosis as heroin dependence according to DSM-IV criteria - No definite history of neurological diseases and psychological problems - Volunteer to participate the study, cooperate to be followed up Exclusion Criteria: - Acute withdrawal state and CIWA score > 9 - With other neurological diseases and psychological problems - With ever brain trauma and damage - With other psychological medications or other substance dependence - With other contraindications to have transcranial magnetic stimulation

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Transcranial magnetic stimulation and Cognitive behavioral therapy
Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy

Locations

Country Name City State
China Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Country where clinical trial is conducted

China, 

References & Publications (4)

Herremans SC, Vanderhasselt MA, De Raedt R, Baeken C. Reduced intra-individual reaction time variability during a Go-NoGo task in detoxified alcohol-dependent patients after one right-sided dorsolateral prefrontal HF-rTMS session. Alcohol Alcohol. 2013 Sep-Oct;48(5):552-7. doi: 10.1093/alcalc/agt054. Epub 2013 May 24. — View Citation

Makani R, Pradhan B, Shah U, Parikh T. Role of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treatment of Addiction and Related Disorders: A Systematic Review. Curr Drug Abuse Rev. 2017;10(1):31-43. doi: 10.2174/1874473710666171129225914. Review. — View Citation

Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, Li X, Zhang Y, Wang Z. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet. 2009 Jun 13;373(9680):2041-53. doi: 10.1016/S0140-6736(09)60660-7. — View Citation

Shen Y, Cao X, Tan T, Shan C, Wang Y, Pan J, He H, Yuan TF. 10-Hz Repetitive Transcranial Magnetic Stimulation of the Left Dorsolateral Prefrontal Cortex Reduces Heroin Cue Craving in Long-Term Addicts. Biol Psychiatry. 2016 Aug 1;80(3):e13-4. doi: 10.1016/j.biopsych.2016.02.006. Epub 2016 Feb 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrence of heroin dependence The rate of relapse of heroin dependence after discharge from hospital 1 month
Primary Recurrence of heroin dependence The rate of relapse of heroin dependence after discharge from hospital 2 month
Primary Recurrence of heroin dependence The rate of relapse of heroin dependence after discharge from hospital 3 month
Primary Recurrence of heroin dependence The rate of relapse of heroin dependence after discharge from hospital 6 month
Secondary Duration of abstinence The total time or period without any intake of heroin during follow-ups 6 months
Secondary Heroin consumption Diaries of heroin intake in different time of the follow-ups 2 weeks, 1 month, 2 months, 3 months and 6 months
Secondary Craving for heroin Craving assessment for heroin by Heroin Craving Questionnaire (HCQ) ranging from 0 to 175. Higher score of HCQ indicates more desire for heroin. 2 weeks, 1 month, 2 months, 3 months and 6 months
Secondary Craving for heroin Craving assessment by Visual Analogue Scale (VAS) for heroin desire ranging 0 to 10. Higher score indicates more desire for heroin. 2weeks, 1 month, 2 months, 3 months and 6 months
Secondary Cognitive assessment Cognitive assessment by Montreal Cognitive Assessment (MoCA) ranging from 0 to 30. Lower score indicates worse cognitive function. 2 weeks, 1 month, 2 months, 3 months and 6 months
Secondary Psychological assessment - Anxiety Psychological assessment by Generalized Anxiety Disorder-7 (GAD-7) ranging from 0 to 21. Higher score indicates more severer anxiety. 2 weeks, 1 month, 2 months, 3 months and 6 months
Secondary Psychological assessment - Depression Psychological assessment by Patient Health Questionnaire-9 (PHQ-9) ranging from 0 to 27. Higher score indicates more severer depression. 2 weeks, 1 month, 2 months, 3 months and 6 months
Secondary Psychological assessment - Sleep Psychological assessment by Pittsburgh Sleep Quality Index (PSQI) ranging from 0 to 21. Higher score indicates worse sleep. 2 weeks, 1 month, 2 months, 3 months and 6 months
See also
  Status Clinical Trial Phase
Completed NCT00577408 - Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone Phase 3
Completed NCT00218309 - Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals Phase 2
Completed NCT00000211 - Treatment Efficacy for Drug Abuse and AIDS Prevention - 2 Phase 2
Completed NCT00000210 - Treatment Efficacy for Drug Abuse and AIDS Prevention - 1 Phase 2
Completed NCT02324725 - Biomarkers of Injectable Extended Release Naltrexone Treatment Phase 4
Withdrawn NCT00000330 - Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5 Phase 2
Completed NCT00249457 - Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2 N/A
Completed NCT00218127 - Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens Phase 2
Completed NCT04133974 - Methadone Induced Memory Retrieval-extinction Procedure in Heroin Addicts N/A
Completed NCT00015288 - Buprenorphine and Naloxone Combination Study - 10 Phase 1
Terminated NCT03711318 - Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals Phase 3
Recruiting NCT02541526 - Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia Phase 3
Active, not recruiting NCT02541513 - An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence Phase 3
Completed NCT01760473 - Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone Phase 3
Terminated NCT01395797 - Pioglitazone for Heroin and for Nicotine Dependence Phase 1/Phase 2
Completed NCT01668706 - Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts N/A
Active, not recruiting NCT00609089 - Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction Phase 1/Phase 2
Completed NCT00684840 - Effects of Stress and Other Factors on Opiate Drug Choice. N/A
Completed NCT00759005 - Effect of Stress on Heroin-Related Memory Retrieval N/A
Completed NCT00218530 - Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1 Phase 1